IAH0968 plus CAPEOX for HER2-positive gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-positive stomach or gastroesophageal junction cancer (a type of protein on the cancer cells) that is advanced or has spread.
- You have not had prior treatment for this cancer (except chemotherapy that finished more than 6 months ago).
- You have at least one tumor that can be measured on scans.
- Your overall health is good enough to be up and about (ECOG score 0 or 1).
- You must use effective birth control during the trial and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
This study tests a new combination treatment for advanced stomach or gastro-esophageal cancer that has not responded to standard treatments. The trial aims to see if the drug combination is safe and effective, potentially offering a new option for people with this type of cancer.
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.